Skip to main content

Advertisement

SpringerLink
Log in

Mesenchymal stem cell therapy for COVID-19 infection

  • Review
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventing and treating COVID-19, mesenchymal stem cell (MSC) therapy can be regarded as a novel and efficient treatment for managing COVID-19 patients. In this review, we explain the pathogenesis of COVID-19 infection in humans and discuss the role of MSCs in suppressing the inflammation and cytokine storm produced by COVID-19. Then, we reviewed the clinical trial and systematic review studies that investigated the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and materials

No data used to support the findings of this study.

References

  • Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, Yesilbag Z, Koyuncu ID, Karaoz E (2021) The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transplant 30:9636897211024942. https://doi.org/10.1177/09636897211024942

    Article  CAS  PubMed  Google Scholar 

  • Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M (2022) Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res Ther 13(1):1–12

    Article  Google Scholar 

  • Antoniou KM, Papadaki HA, Soufla G, Kastrinaki MC, Damianaki A, Koutala H, Spandidos DA, Siafakas NM (2010) Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF). Respir Med 104(10):1535–1542

    Article  PubMed  Google Scholar 

  • Arabpour E, Khoshdel S, Tabatabaie N, Akhgarzad A, Zangiabadian M, Nasiri MJ (2021) Stem cells therapy for COVID-19: a systematic review and meta-analysis. Front Med 8:737590

    Article  Google Scholar 

  • Baer PC (2014) Adipose-derived mesenchymal stromal/stem cells: an update on their phenotype in vivo and in vitro. World J Stem Cells 6(3):256

    Article  PubMed  PubMed Central  Google Scholar 

  • Baer PC, Geiger H (2012) Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int 2012:1–11

    Article  Google Scholar 

  • Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A (2007) Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-and allogeneic-stimulated lymphocytes in vitro. Rheumatology 46(3):403–408

    Article  CAS  PubMed  Google Scholar 

  • Cai M, Shen R, Song L, Lu M, Wang J, Zhao S, Tang Y, Meng X, Li Z, He Z-X (2016) Bone marrow mesenchymal stem cells (BM-MSCs) improve heart function in swine myocardial infarction model through paracrine effects. Sci Rep 6(1):28250

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao JX, You J, Wu LH, Luo K, Wang ZX (2022) Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 10(27):9714–9726. https://doi.org/10.12998/wjcc.v10.i27.9714

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen C-Y, Chen W-C, Hsu C-K, Chao C-M, Lai C-C (2022) The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J Infect Public Health. https://doi.org/10.1016/j.jiph.2022.07.001

    Article  PubMed  PubMed Central  Google Scholar 

  • Chu M, Wang H, Bian L, Huang J, Wu D, Zhang R, Fei F, Chen Y, Xia J (2022) Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia. Stem Cell Rev Rep 18(6):2152–2163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Klerk E, Hebrok M (2021) Stem cell-based clinical trials for diabetes mellitus. Front Endocrinol 12:631463

    Article  Google Scholar 

  • Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, Mariana N, Antarianto RD, Liem IK, Kispa T (2021) Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med 10(9):1279–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duffy MM, Ritter T, Ceredig R, Griffin MD (2011) Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2:1–9

    Article  Google Scholar 

  • Ercelen ON, Pekkoc-Uyanik KC, Alpaydin N, Gulay GR, Simsek M (2021) Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. Stem Cell Rev Rep 17:1917–1925

    Article  Google Scholar 

  • Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F, Dehghan-Manshadi SA, Kazemnejad S (2022) Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Res Ther 13(1):96

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Cortes P, Rico L, Büscher D, Delgado M (2010) Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 69(01):241–248

    Article  CAS  PubMed  Google Scholar 

  • Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y (2022) Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial. Front Immunol 13:932360. https://doi.org/10.3389/fimmu.2022.932360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hashemian S-MR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini S-E, Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E (2021) Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther 12(1):1–12

    Article  Google Scholar 

  • Javed A, Karki S, Sami Z, Khan Z, Shree A, Sah BK, Ghosh S, Saxena S (2022) Association between mesenchymal stem cells and covid-19 therapy: systematic review and current trends. BioMed Res Int 2022:1–17

    Article  Google Scholar 

  • Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, Khodadoust MA, Ganjali R, Tafreshian AR, Tavakol-Afshari J (2022) Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther 13(1):283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Karyana M, Djaharuddin I, Rif’ati L, Arif M, Choi MK, Angginy N, Yoon A, Han J, Josh F, Arlinda D, Narulita A, Muchtar F, Bakri RA, Irmansyah S (2022) Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther 13(1):134. https://doi.org/10.1186/s13287-022-02812-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kavianpour M, Saleh M, Verdi J (2020) The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther 11(1):1–19

    Article  Google Scholar 

  • Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S (2014) Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 6(5):552

    Article  PubMed  PubMed Central  Google Scholar 

  • Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC (2021) Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 10(5):660–673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee S, Choi E, Cha M-J, Hwang K-C (2015) Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxidat Med Cell Long 2015:1–9

    Article  Google Scholar 

  • Leuning DG, Beijer NR, Du Fossé NA, Vermeulen S, Lievers E, Van Kooten C, Rabelink TJ, Boer JD (2018) The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment. Sci Rep 8(1):7716

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  • Li N, Hua J (2017) Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci 74:2345–2360

    Article  ADS  CAS  PubMed  Google Scholar 

  • Li T, Xia M, Gao Y, Chen Y, Xu Y (2015) Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther 15(9):1293–1306

    Article  CAS  PubMed  Google Scholar 

  • Li C, He Q, Qian H, Liu J (2021a) Overview of the pathogenesis of COVID-19 (Review). Exp Ther Med 22(3):1011. https://doi.org/10.3892/etm.2021.10444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li C, Zhao H, Wang B (2021b) Mesenchymal stem/stromal cells: developmental origin, tumorigenesis and translational cancer therapeutics. Transl Oncol 14(1):100948

    Article  CAS  PubMed  Google Scholar 

  • Li T-T, Zhang B, Fang H, Shi M, Yao W-Q, Li Y, Zhang C, Song J, Huang L, Xu Z (2023) Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 92:104600

    Article  PubMed  PubMed Central  Google Scholar 

  • Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K (2019) Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int 2019

  • Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F (2013) Mesenchymal stem cells generate a CD4+ CD25+ Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 4:1–12

    Article  Google Scholar 

  • Mason RJ (2020) Pathogenesis of COVID-19 from a cell biology perspective. In: (Vol. 55): Eur Respiratory Soc.

  • Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, Yang T, Shi L, Fu J, Jiang T (2020) Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther 5(1):172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V (2020) COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog 16(8):e1008762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, Diehl J-L, Demoule A, Annane D, Marois C (2022) Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care 26(1):48

    Article  PubMed  PubMed Central  Google Scholar 

  • Mousavizadeh L, Ghasemi S (2021) Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect 54(2):159–163

    Article  CAS  PubMed  Google Scholar 

  • Nachmias B, Zimran E, Avni B (2022) Mesenchymal stroma/stem cells: haematologists’ friend or foe? Br J Haematol 199(2):175–189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Qu W, Wang Z, Engelberg-Cook E, Yan D, Siddik AB, Bu G, Allickson JG, Kubrova E, Caplan AI, Hare JM (2022) Efficacy and safety of MSC cell therapies for hospitalized patients with COVID-19: a systematic review and meta-analysis. Stem Cells Transl Med 11(7):688–703

    Article  PubMed  PubMed Central  Google Scholar 

  • Rao V, Thakur S, Rao J, Arakeri G, Brennan PA, Jadhav S, Sayeed MS, Rao G (2020) Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19. Med Hypoth 143:109845

    Article  CAS  Google Scholar 

  • Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leitão CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A (2022) Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther 13(1):122. https://doi.org/10.1186/s13287-022-02796-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sadeghi S, Soudi S, Shafiee A, Hashemi SM (2020) Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action. Life Sci 262:118493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, Siavashi V, Aghaghazvini L, Khoundabi B, Abdoli S (2021) Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther 12(1):1–13

    Article  Google Scholar 

  • Sanabria-de la Torre R, Quiñones-Vico MI, Fernández-González A, Sánchez-Díaz M, Montero-Vílchez T, Sierra-Sánchez Á, Arias-Santiago S (2021) Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review. J Clin Med 10(13):2991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, Sagredo V, Álvarez-Avello J-M, Guerrero JE, Pérez-Calvo C (2020) Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 25

  • Satarker S, Nampoothiri M (2020) Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch Med Res 51(6):482–491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N (2020) Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29(12):747–754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K (2021) Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol 12:749192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang F-S (2021) Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther 6(1):339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Wang FS (2022) Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 75:103789. https://doi.org/10.1016/j.ebiom.2021.103789

    Article  CAS  PubMed  Google Scholar 

  • Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L (2020) Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 11(1):1–11

    Article  Google Scholar 

  • Wang Y, Tian M, Wang F, Heng BC, Zhou J, Cai Z, Liu H (2019) Understanding the immunological mechanisms of mesenchymal stem cells in allogeneic transplantation: from the aspect of major histocompatibility complex class I. Stem Cells Dev 28(17):1141–1150

    Article  PubMed  Google Scholar 

  • Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L (2021a) Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis. Stem Cells Dev 30(19):947–969

    Article  CAS  PubMed  Google Scholar 

  • Wang L, Li Y, Xu M, Deng Z, Zhao Y, Yang M, Liu Y, Yuan R, Sun Y, Zhang H (2021b) Regulation of inflammatory cytokine storms by mesenchymal stem cells. Front Immunol 12:726909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, Ye P, Li H, Yu L, Zhou X (2021) Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med 11(2):e297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yao W, Dong H, Qi J, Zhang Y, Shi L (2022) Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: a systematic review and meta-analysis. EClinicalMedicine 51:101545

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang Y, Ding J, Ren S, Wang W, Yang Y, Li S, Meng M, Wu T, Liu D, Tian S (2020) Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 11:1–6

    Google Scholar 

  • Zhang M, Yan X, Shi M, Li R, Pi Z, Ren X, Wang Y, Yan S, Wang Y, Jin Y (2022) Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis. Global Health Res Policy 7(1):1–13

    Article  Google Scholar 

  • Zhu Y-G, Shi M-M, Monsel A, Dai C-X, Dong X, Shen H, Li S-K, Chang J, Xu C-L, Li P (2022) Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther 13(1):1–10

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Declared none.

Author information

Authors and Affiliations

  1. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Seyyed Mohammad Matin Alavi-Dana & Yazdan Gholami

  2. Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Mohammadreza Meghdadi

  3. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Azadi Sq, Vakil Abad Highway, Mashhad, 9177948564, Iran

    Mohammad Saleh Fadaei & Vahid Reza Askari

  4. Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran

    Vahid Reza Askari

  5. International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran

    Vahid Reza Askari

Authors
  1. Seyyed Mohammad Matin Alavi-Dana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yazdan Gholami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammadreza Meghdadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Saleh Fadaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vahid Reza Askari
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to writing the project and read and approved the final manuscript submission. This study has been done by the authors mentioned in this article, and the authors will bear all responsibilities related to the contents of this article.

Corresponding author

Correspondence to Vahid Reza Askari.

Ethics declarations

Conflict of Interest

The authors declare that they do not have any conflict of interest.

Human and animal rights

No animals/humans were used for studies that are the basis of this research.

Ethics approval and consent to participate

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alavi-Dana, S.M.M., Gholami, Y., Meghdadi, M. et al. Mesenchymal stem cell therapy for COVID-19 infection. Inflammopharmacol 32, 319–334 (2024). https://doi.org/10.1007/s10787-023-01394-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-023-01394-8

Keywords

Search

Navigation